The Food and Drug Administration on Saturday granted emergency authorization to the experimental antibody treatment given to President Trump last month when he developed covid-19, the disease caused by the novel coronavirus.
The drug, made by Regeneron Pharmaceuticals, is designed to prevent infected people from developing severe illness. Instead of waiting for the body to develop its own protective immune response, the drug imitates the body’s natural defenses. It is the second drug of this type — called a monoclonal antibody — to be cleared for treating covid-19. The FDA authorized Eli Lilly & Co.’s drug on Nov. 9.
Regeneron’s drug is a cocktail of two monoclonal antibodies, called casirivimab and imdevimab. The FDA said in authorizing the cocktail that it